Research Agreement to assess Noile’s PRIME technology was made between and by Noile and Daiichi Sankyo.
We are pleased to post the news that Daiichi Sankyo Co.,Ltd., has made a research agreement to assess PRIME technology with Noile-Immune (herein, Noile), one of our portfolio companies. Until now, Noile has made a series of wonderful collaborations with top tier global biotechs and pharmaceutical companies including top three major Japanese pharmaceutical companies: Takeda, Chugai, and Daiichi Sankyo, and is now conducting human clinical studies targeting solid cancer either for itself (NIB101) or with the help of partner company (NIB102). The number of pipeline entering into human clinical stage is expected to increase gradually.
Noile-Immune Biotech Enters Collaboration with
DAIICHI SANKYO COMPANY, LIMITED on Technology
Tokyo, Japan (October 25, 2021) - Noile-Immune Biotech Inc. (“Noile-Immune”) today
announced that Noile-Immune and DAIICHI SANKYO COMPANY, LIMITED (“Daiichi
Sankyo”) have entered into the agreement regarding PRIME (Proliferation inducing and
migration enhancing) technology assessment.
PRIME technology has a capability of not only enhancing the functions of gene-modified immune
cells such as CAR-T cells, but also improving the ability of patient's own immune systems to treat
cancer1). Noile-Immune has the exclusive right to implement PRIME technology.
Under this agreement, Daiichi Sankyo will evaluate Noile-Immune’s PRIME technology with
collaborative works with Noile-Immune, and Daiichi Sankyo will pay Noile-Immune the
technology access fee. Further details of this agreement are not disclosed.
1) Adachi K et al. Nat Biotechnol, 2018;36(4):346-351.